LYFT Inc vs Medpace Holdings Inc — how do they compare? LYFT Inc trades at $17.5 (market cap $6.64B), while Medpace Holdings Inc trades at $609.54 (market cap $16.90B). The key difference: Medpace Holdings Inc is far larger — about 2.5× LYFT Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, LYFT Inc nearer its low. Which is the better fit depends on your goals.
| LYFT | MEDP | |
|---|---|---|
Market Cap | $6.64B | $16.90B |
Sector | Industrials | Technology |
52-Week High | $24.57 | $620.59 |
52-Week Low | $12.65 | $393.42 |
Enterprise Value | $6.11B | $16.52B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MEDP trades at $590.67, up 0.97% on the day, near its consensus price target of $599.57. The stock shows bullish momentum with a golden cross formation and strong institutional interest, while recent Q2 2026 earnings beat estimates with EPS of $4.25 versus $3.98 expected. Revenue growth remains robust, projected to rise from $2.53 billion in 2025 to $2.8 billion in 2026, supporting a premium valuation with a P/E of 35.4.
Outlook is positive given earnings consistency and raised 2026 guidance, but risks include high valuation sensitivity and a shareholder lawsuit investigation. The stock offers growth potential from a strong backlog and net book-to-bill ratio of 1.13x, though investors should monitor legal developments and competitive pressures in medical services.
Trailing returns across standard periods
Latest headlines on both assets
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →